

Na_2CO_3 solution (100 mL). The organic phase was separated, dried, and concentrated to give the crude ethyl 3-ethylimidazo[1,5-*a*]pyridine-1-carboxylate (4.0 g, 85%). This ester was hydrolyzed to acid **20** (2.5 g, 70%) by the method described for **19**. A suspension of **20** (0.22 g, 1.1 mmol) was stirred with SOCl_2 (3 mL) at room temperature for 3 h. The excess SOCl_2 was removed by evaporation; the residue was suspended in CH_2Cl_2 (10 mL) and treated with a solution of **15** (0.2 g, 1.4 mmol) and Et_3N (0.4 mL) in CH_2Cl_2 (10 mL). The reaction mixture was stirred for 18 h and washed with saturated NaHCO_3 (20 mL), and the lower organic phase was dried and concentrated. Purification of the residue by column chromatography on alumina, eluting with CHCl_3 , gave **9**: 0.22 g (65%); mp 107–108 °C; ^1H NMR (CDCl_3) δ 8.25 (dm, 1), 7.77 (dm, 1), 7.71 (br d, 1, NH), 6.94 (dd, 1), 6.69 (tm, 1), 2.96 (q, 2, CH_2), 2.32 (s, 3, NCH_3), 1.46 (t, 3, CH_3). Anal. ($\text{C}_{17}\text{H}_{24}\text{N}_4\text{O}$) C, H, N.

endo-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-3-ethylimidazo[1,5-*a*]pyridine-1-carboxamide (10). By following the procedure described for **9**, **20** (0.22 g, 1.1 mmol) was converted to **10**: 0.2 g (55%); mp 155–157 °C; ^1H NMR (CDCl_3) δ 8.28 (dm, 1), 7.77 (dm, 1), 6.96–6.85 (m, 2), 6.68 (tm, 1), 2.98 (q, 2, CH_2), 2.42 (s, 3, NCH_3), 1.44 (t, 3, CH_3). Anal. ($\text{C}_{18}\text{H}_{26}\text{N}_4\text{O}$) C, H, N.

endo-N-(2-Methyl-2-azabicyclo[2.2.2]octan-5-yl)-1-methyl-1H-indazole-3-carboxamide (12). A mixture of *endo*- and *exo*-5-amino-2-methyl-2-azabicyclo[2.2.2]octane (0.3 g, 2.1 mmol) was converted to title compound **12**, which was separated from its *exo* isomer by column chromatography on alumina, eluting with CH_2Cl_2 containing increasing quantities of CHCl_3 : 0.15 g (24%); mp 107–109 °C; ^1H NMR (CDCl_3) δ 8.36 (dt, 1), 7.05 (d, 1), 4.48–4.35 (m, 1, 5-H), 4.10 (s, 3, NCH_3), 2.79 (d, 2, $J = 2$ Hz), 2.76–2.67 (m, 1), 2.67–2.59 (m, 1). Anal. ($\text{C}_{16}\text{H}_{22}\text{N}_4\text{O}$) C, H, N.

Pharmacology. The compounds were evaluated for antagonism of the Bezold-Jarisch reflex evoked by 5-HT in the anesthetized rat by the method of Fozard et al.^{10,39} Male rats

(260–290 g) were anesthetized with urethane (1.25 g/kg ip) and blood pressure and heart rate were recorded. A submaximal dose of 5-HT (6 $\mu\text{g/kg}$ iv) was given repeatedly and the changes in heart rate were quantified. Compounds were given intravenously prior to administration of 5-HT and the dose required to reduce the 5-HT evoked response to 50% of the control response (ID_{50}) was determined. The antiemetic activity was assessed in the ferret. Food was withdrawn 12 h before experimentation and emesis was induced by iv injection of either cisplatin (10 mg/kg) or by a combination of cyclophosphamide (80 mg/kg) and doxorubicin (6 mg/kg). To evoke emesis by X-irradiation, ferrets were exposed to X-rays derived from the tungsten anode of a Machlett Model OEG-50 operating at 50 kV and 20 mA through a beryllium window with a 0.18-mm aluminum filter placed about 25 cm above the ferret for 10.4 min. Compound **6g** was given either as a divided dose 30 min before and 45 min after cisplatin, 30 min before and 30 min after doxorubicin/cyclophosphamide, or as a single dose 5 min before exposure to X-irradiation. The latency period for the onset of emesis and the number of emetic episodes was compared with saline-based controls. Antagonism of 5-HT evoked contraction of guinea pig ileum and 5-HT-evoked tachycardia was assessed by the literature procedure.³⁹ pA_2 values were determined by the method of Arunlakshana and Schild.⁴⁰ Binding to 5-HT₁ and 5-HT₂ receptors was estimated by the methods of Bennett and Snyder⁴¹ and Leysen et al.,⁴² respectively, using rat cortical membranes, [³H]-5-HT (4 nmol), and [³H]ketanserin (0.5 nmol).

Acknowledgment. We thank A. Dunbar and W. D. Miner for biological testing and D. Smith for the NMR data.

(40) Arunlakshana, O.; Schild, H. O. *Br. J. Pharmacol. Chemother.* 1959, 14, 48.

(41) Bennett, J. P.; Snyder, S. H. *Mol. Pharmacol.* 1976, 16, 373.

(42) Leysen, J. E.; Niemegeers, J. E.; Van Neuten, J. M.; Laduron, P. M. *Mol. Pharmacol.* 1982, 21, 301.

(39) Sanger, G. J. *Br. J. Pharmacol.* 1987, 91, 77.


5-Hydroxytryptamine (5-HT₃) Receptor Antagonists. 2. 1-Indolinecarboxamides

José Bermudez, Steven Dabbs, Karen A. Joiner, and Frank D. King*

Beecham Pharmaceuticals Research Division, The Pinnacles, Harlow, Essex, England. Received October 12, 1989

Indazole **1** has previously been shown to be a potent and selective 5-HT₃ receptor antagonist. A novel series of potent 5-HT₃ receptor antagonists, 1-indolinecarboxamides **2a–q** and 1-indolecarboxamides **3b,i,j,k**, is described. The activity of the indolines suggests that aromaticity of the 5-membered ring is not an essential requirement for potency provided that an "in plane" orientation of the carbonyl group is favored. Upon the basis of this hypothesis indene **9** was prepared in which the "in plane" orientation of the carbonyl group is maintained by conjugation with the aromatic ring through the sp^2 hybridized carbon. It was also found to be a potent 5-HT₃ receptor antagonist.

The first paper in this series described the synthesis and activity of a novel series of potent 5-hydroxytryptamine (5-HT₃) receptor antagonists from which indazole **1** (BRL




43694), was highlighted,¹ which is currently undergoing clinical trials for the inhibition of emesis evoked by cancer therapy. In that paper we proposed that, for high potency, the carbonyl link must be in the same plane as the aro-

matic rings. We also speculated on the relative importance of the aromaticity of the two rings of the bicyclic indazole with respect to its activity. This paper describes our results obtained from compounds in which the 5-membered ring of a fused bicyclic system is nonaromatic, but in which a planar relationship of the amide and the aromatic ring is maintained with the sp^2 hybridization of an aromatic amide. The synthesis and activities of 1-indolinecarboxamides **2a–q** (Table I) are described, together with the closely related 1-indolecarboxamides **3b,i,j,k** (Table II). Upon the basis of the conclusions regarding structure–activity, indene **9** was also prepared and its activity was investigated.

Chemistry


1-Indolinecarboxamides **2a–q** were synthesized (Scheme I) from the appropriate indoline **4** and either *endo*-8-methyl-8-azabicyclo[3.2.1]octan-3-amine or *endo*-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine¹ via trichloromethyl carbamate **5** (method 1), carbamoyl chloride **6**

(1) Bermudez, J.; Fake, C. S.; Joiner, G. F.; Joiner, K. A.; King, F. D.; Sanger, G. J. *J. Med. Chem.* Preceding paper in this issue.

Table I. Structure and Analytical and Pharmacological Data of **2a–q**, **8**, and **9**



no.	R ¹	R ²	R ³	R ⁴	R ⁵	X	n	method ^a	% yield ^b	formula	mp, °C	anal.	inhibn of BJ reflex	
													ID ₅₀ , µg/kg iv (± SEM)	no. of rats
1 ^d			BRL 43694										0.7 ± 0.2	9
2a	Me	H	H	H	H	NH	3	1	52	C ₁₈ H ₂₅ N ₃ O·0.5H ₂ O	176–178	C, H, N	12.5 ± 2.5	3
2b	Me	H	H	H	H	NH	2	1	48	C ₁₇ H ₂₃ N ₃ O	153–154	C, H, N	1.4 ± 0.1	6
2c	Et	H	H	H	H	NH	2	1	25	C ₁₈ H ₂₅ N ₃ O	140–141	C, H, N	>10	3
2d	Me	H	H	H	H	O	2	a	31	C ₁₇ H ₂₂ N ₂ O ₂	133–134	C, H, N ^c	4.3 ± 1.3	3
2e	Me	F	H	H	H	NH	2	3	18	C ₁₇ H ₂₂ FN ₃ O	299–300	C, H, N	>10	3
2f	Me	Cl	H	H	H	NH	2	2	19	C ₁₇ H ₂₂ ClN ₃ O	149–150	C, N, Cl	>10	3
2g	Me	MeO	H	H	H	NH	2	1	45	C ₁₈ H ₂₅ N ₃ O ₂ ·H ₂ O	142–145	C, H, N	>10	3
2h	Me	NO ₂	H	H	H	NH	2	1	62	C ₁₇ H ₂₂ N ₄ O ₃	176–178	C, H, N	>10	3
2i	Me	H	Me	H	H	NH	2	3	23	C ₁₈ H ₂₅ N ₃ O·HCl	268–270	C, H, N	3.0 ± 0.4	3
2j	Me	H	Et	H	H	NH	2	1	76	C ₁₉ H ₂₇ N ₃ O·HCl·H ₂ O	263–264	C, H, N	1.5 ± 0.5	3
2k	Me	H	Ph	H	H	NH	2	2	91	C ₂₃ H ₂₇ N ₃ O·HCl	319–320	C, H, N	1.8 ± 0.2	3
2l	Me	H	H	H	Me	NH	2	2	78	C ₁₉ H ₂₅ N ₃ O·HCl	292–293	C, H, N	0.8 ± 0.3	3
2m	Me	H	Me	H	Me	NH	2	2	35	C ₁₉ H ₂₇ N ₃ O	134–136	C, H, N	0.5 ± 0.2	4
2n	Me	H	Me	Me	Me	NH	2	2	50	C ₂₀ H ₂₉ N ₃ O·HCl	225–226	C, H, N	1.4 ± 0.4	4
2o	Me	H	-(CH ₂) ₂ -	H	H	NH	2	2	23	C ₁₉ H ₂₅ N ₃ O	196–197	C, H, N	3.5 ± 1.0	3
2p	Me	H	-(CH ₂) ₄ -	H	H	NH	2	2	49	C ₂₁ H ₂₉ N ₃ O	191–193	C, H, N	1.2 ± 0.6	3
2q	Me	H	-(CH ₂) ₅ -	H	H	NH	2	2	35	C ₂₂ H ₃₁ N ₃ O	188–189	C, H, N	3.6 ± 1.0	3
8	Me					NH	2	2	75	C ₁₈ H ₂₅ N ₃ O·HCl	269–271	C, H, N	>100	3
9	Me					NH	2	a	86	C ₂₀ H ₂₇ ClN ₃ O	>300	C, H, N	1.0 ± 0.2	4

^a See the Experimental Section. ^b Yield for final stage only. ^c H: calcd, 7.74; found, 8.19. ^d Reference 1.

Table II. Structure and Analytical and Pharmacological Data of **3b,i,j,k**


no.	R ³	formula	mp, °C	anal.	% yield	inhibn of BJ reflex	
						ID ₅₀ , µg/kg iv (± SEM)	no. of rats
3b	H	C ₁₇ H ₂₁ N ₃ O·HCl·0.4H ₂ O	258–260	C, H, N	68	7.1 ± 1.7	3
3i	Me	C ₁₈ H ₂₃ N ₃ O·HCl·H ₂ O	158–161	C, H, N	40	1.6 ± 0.2	3
3j	Et	C ₁₉ H ₂₅ N ₃ O·HCl·0.25H ₂ O	210–213	C, H, N	40	2.0 ± 0.7	4
3k	Ph	C ₂₃ H ₂₅ N ₃ O·HCl	264–265	C, H, N	40	5.1 ± 1.3	3

(method 2), or *N*-succinimidyl carbamate **7** (method 3). 1,2,3,4-Tetrahydroquinoline **8** was prepared similarly by method 2. When R⁴ = H, 1-indolinecarboxamides **2b,i,j,k** were dehydrogenated with DDQ² to give indoles **3b,i,j,k**. Indene **9** was prepared from acid **10** via the acid chloride.⁴



Results and Discussion

The 5-HT₃ receptor antagonist potency of the compounds was assessed by their ability to antagonise the 5-HT-evoked reflex bradycardia [Bezold–Jarisch (BJ) reflex] in rats.⁵ This effect is mediated by activation of 5-HT₃ receptors located in the wall of the right ventricle.⁶

The low potency of granatane **2a** (Table I) and the high potency of tropane **2b** parallels the structure–activity relationship of the 3-indolecarboxamides rather than that

(4) Fozard, J. R. *Neuropharmacol.* **1984**, *23*, 1473.


(5) Paintal, A. S. *Physiol. Rev.* **1973**, *53*, 159.

(6) Giger, R. K. A.; Donatsch, P.; Engel, G.; Richardson, B.; Stadler, P. A. *Proceedings of the VIIIth International Symposium on Medicinal Chemistry*, Uppsala, 1984; p 133.

(2) Preobrazhenskaya, M. N. *Russ. Chem. Rev.* **1967**, *36*, 753.

(3) Yoneda, R.; Terada, T.; Harusawa, S.; Kurihara, T. *Heterocycles* **1985**, *23*, 557.

Scheme I. Synthesis of Indolines 2a-q



of the 3-indazolecarboxamides.¹ *N*-Ethyltropine 2c was much less potent than the *N*-methyl analogue 2b. A similar steric constraint has been previously observed for indole esters.⁷ Carbamate 2d was also less potent than urea 2b. For the previously reported indazole series, substitution in the benzo ring with groups larger than F resulted in a marked reduction in potency. Steric intolerance was even more marked in this series with all the 5-substituted analogues 2e-h being much less potent than 2b. The related 1,2,3,4-tetrahydroquinolyl urea 8 was inactive within the dose range tested. This may be a consequence of the greater steric interaction between the urea linkage and both the peri-8H atom and the two 2H atoms of the tetrahydro ring which would destabilize the "in plane" orientation of the carbonyl. Alternatively this lack of activity may result from the different relative orientation of the benzo ring and the tropane side chain.

The introduction of a 3-methyl in 2i or the larger 3-phenyl in 2k failed to increase potency. It was previously reported that the 2-methylindazoles were very much less potent than the 1-methyl isomers.¹ In marked contrast, 2-methylindolines retained high potency. 3-Unsubstituted 2i, 3-monomethyl 2m, and 3,3-dimethyl 2n were all found to be potent 5-HT₃ receptor antagonists. These results can still be rationalized in terms of the "in plane" hypothesis for the linking carbonyl. At the nonaromatic sp³ hybridized 2-C atom of the indoline, the 2-methyl substituent can sit below the plane of the ring. This would allow a favored "in plane" orientation of the carbonyl link. For the fully aromatic indazoles, the 2-methyl substituent is held in the plane of the aromatic ring by the sp² hybridization, which would result in a considerable steric hindrance to the "in plane" orientated link.¹ 3,3-spiro compounds 2o,p,q were less potent with potency being maximal for 5-membered 2p. Although indole analogue 3b was less potent than its indoline counterpart 2b, reasonable potency was maintained for the 3-substituted indoles 3i and 3j (Table II).

Assuming that the indolines retain the "in plane" orientation of the carbonyl link via the sp² hybridization of the N atom, a similarly favored "in plane" orientation could be achieved by attaching the linking carbonyl via a non-aromatic sp² hybridized C atom. This was achieved with indene 9, in which the 3,3-dimethyl substitution maintains the double bond in the 1,2-position. It was subsequently

found to be a highly potent 5-HT₃ receptor antagonist (Table I).

In conclusion, the results with indolines 2b,d,i-q and indene 9 show that aromaticity in the 5-membered ring of the bicyclic aromatic nucleus is not essential for potency. This would imply that the 5-membered ring is merely acting as a "spacer" unit to ensure the optimal angular and spatial orientation of the carbonyl linkage, the basic side chain, and the aromatic ring. Further work in our laboratories has shown that the active geometry can be retained in a monocyclic aromatic derivative; this will form the basis of the next paper in the series.

Experimental Section

Chemistry. Melting points are uncorrected. Elemental analyses indicated are within 0.4% of the theoretical values unless specified. All evaporations of solvent were carried out by rotary evaporation under reduced pressure and organic extracts were dried over Na₂SO₄ unless specified. For chromatography the alumina and silica used was Fluka TLC type H. Light petroleum refers to the fraction boiling between 60 and 80 °C. The yields quoted are nonoptimized and generally refer to the result of a single experiment. Indolines 4 were either commercially available or prepared by standard synthetic procedures which have been described in detail elsewhere.⁷

General Procedure for the Preparation of the 1-Indoline Ureas 2a-c,e-q and 8. Method 1. A solution of trichloromethyl chloroformate (3.7 g, 0.02 mol) in dry CH₂Cl₂ (20 mL) was added dropwise to a cooled solution of the appropriate indoline (0.02 mol) and Et₃N (2.0 g, 0.02 mol) in dry CH₂Cl₂ (100 mL). The reaction was stirred at room temperature for 2 h, washed with H₂O (5 mL) and 5 N HCl (5 mL), and dried. The solvent was removed and the residue was purified by filtration through a short alumina column, eluting with CH₂Cl₂ to give the appropriate trichloromethyl carbamate 5. A solution of 5 (0.01 mol) and the appropriate diamine (0.01 mol) in dry toluene (100 mL) was heated under reflux for 24 h. The solvent was evaporated and the residue was partitioned between CH₂Cl₂ (200 mL) and saturated K₂CO₃ (40 mL). The organic phase was separated, dried, and concentrated, and the residue was purified by column chromatography on alumina, eluting with CHCl₃, to give the appropriate carbamates, which were either crystallized from EtOAc or converted to their hydrochloride salt.

Method 2. A solution of the appropriate indoline or 1,2,3,4-tetrahydroquinoline (0.02 mol) and Et₃N (2.0 g, 0.02 mol) in dry CH₂Cl₂ (20 mL) was added, dropwise, to a cooled and stirred solution of COCl₂ (18 mL of 12.5% w/w solution in toluene) in dry CH₂Cl₂ (30 mL). The reaction was stirred at 0 °C for 1 h, poured into pentane (400 mL), washed with 5 N H₂SO₄ (30 mL) and brine (30 mL), and dried. The solvent was evaporated to give carbamoyl chloride 6, which was used without further purification. A solution of 6, (0.01 mol) the appropriate diamine (0.01 mol) and Et₃N (1.0 g, 0.01 mol) in dry CH₂Cl₂ (100 mL) was stirred at room temperature for 18 h. The solvent was evaporated and the residue was partitioned between Et₂O (50 mL) and 5 N HCl (20 mL). The aqueous phase was separated and basified with K₂CO₃, and the product was extracted into CH₂Cl₂ (3 × 50 mL). The combined organic extracts were dried and concentrated and the residue was purified by filtration through a short alumina column, eluting with CHCl₃. The product was either crystallized from EtOAc or converted to its hydrochloride salt.

Method 3. A solution of the appropriate indoline (0.02 mol) and *N,N*-disuccinimidyl carbonate (5.1 g, 0.02 mol) in dry toluene (100 mL) was stirred at room temperature for 18 h. The solvent was evaporated, the residue was dissolved in CH₂Cl₂ (100 mL), and the solution was washed with 5 N HCl (10 mL), saturated K₂CO₃, and finally brine (30 mL). The organic phase was dried and concentrated, and the residue was purified by filtration through a short silica column, eluting with CH₂Cl₂, to give carbamate 7. A solution of 7 (0.01 mol) and *endo*-8-methyl-8-azabicyclo[3.2.1]octan-3-amine (1.4 g, 0.01 mol) in dry toluene (100 mL) was heated under reflux for 18 h. The solvent was evaporated and the residue was partitioned between CH₂Cl₂ (200 mL) and saturated K₂CO₃ (40 mL). The organic phase was dried, and concentrated, and the residue was purified by chromatography

(7) Joiner, K. A.; King, F. D. *European Patent* 0247,266, 1987.

on alumina, eluting with CHCl_3 . The product was either crystallized from EtOAc or converted into its hydrochloride salt.

endo-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 1-Indolinecarboxylate (2d). A solution of tropine (1.13 g, 8 mmol) and *KO-t-Bu* (0.94 g, 8.4 mmol) in dry diglyme (50 mL) was stirred at room temperature for 1 h and then evaporated. The residue was treated with a solution of carbamate **5** (2.4 g, 8.5 mmol) in dry diglyme (50 mL) and heated under reflux for 36 h. The solvent was evaporated and the residue was partitioned between 5 N HCl (10 mL) and Et_2O (30 mL). The aqueous phase was separated and basified with K_2CO_3 and the product was extracted into CH_2Cl_2 (3 \times 50 mL). The combined organic extracts were dried and concentrated and the residue was purified by column chromatography on alumina, eluting with CH_2Cl_2 . Crystallization from Et_2O afforded **2d** (0.7 g).

General Procedure for Preparation of 1-Indolinecarboxamides 3b,i,j,k. A solution of the monohydrochloride salt of the appropriate 1-indolinecarboxamide **2b,i,j,k** (1.6 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (0.41 g, 1.8 mmol) in dry CHCl_3 (100 mL) was heated under reflux for 6 h. The cooled reaction mixture was washed with saturated K_2CO_3 (20 mL), dried, and concentrated. The residue was filtered through a short alumina column, eluting with CHCl_3 to give the appropriate indole-1-carboxamide, which was converted into its hydrochloride salt.

endo-N-(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl)-3,3-dimethyl-1-indenecarboxamide Hydrochloride (9). A stirred solution of 3,3-dimethylindene-1-carbonyl chloride (1.1 g, 5.3 mmol) in dry CH_2Cl_2 (50 mL) at 0 °C was treated with a solution of *endo*-8-methyl-8-azabicyclo[3.2.1]octan-3-amine (0.8 g, 5.7 mmol) in dry CH_2Cl_2 (50 mL). After 2 h the reaction mixture was diluted with ether (300 mL) to give **9** (1.6 g): ^1H NMR ($\text{DMSO}-d_6$) δ 8.20 (br s 1 H), 7.80–7.70 (m, 1 H), 7.48–7.38 (m, 1 H), 7.30–7.15 (m, 2 H), 7.03 (s, 1 H), 2.64 (s, 3 H), 1.32 (s, 6 H).

Pharmacology. The compounds were evaluated for antagonism of the BJ reflex evoked by 5-HT in the anesthetized rat by the method of Fozard.^{4,8} Male rats (260–290 g) were anesthetized with urethane (1.25 g/kg ip) and blood pressure and heart rate were recorded. A submaximal dose of 5-HT (6 $\mu\text{g/kg}$ iv) was given repeatedly, and the changes in heart rate were quantified. Compounds were given intravenously prior to administration of 5-HT, and the dose required to reduce the 5-HT-evoked response to 50% of the control response (ID_{50}) was determined.

Acknowledgment. We thank C. S. Fake and G. J. Sanger for their help and support.

(8) Sanger, G. J. *Br. J. Pharmacol.* 1987, 91, 77.


5-Hydroxytryptamine (5-HT₃) Receptor Antagonists. 3. Ortho-Substituted Phenylureas

José Bermudez, Steven Dabbs, and Frank D. King*

Beecham Pharmaceuticals Research Division, The Pinnacles, Harlow, Essex, England. Received October 12, 1989


A novel series of potent 5-HT₃ receptor antagonists, ortho-substituted phenylureas **6a–z**, is described in which the 5-membered ring of the previously reported indazoles and indolines has been replaced by an intramolecular hydrogen bond. High potency was found both for carbamate **6a** and urea **6b**. Granatane **6c** was less potent than the equivalent tropane. Phenylurea **11c** lacking the ortho substituent was inactive. Whereas further substitution could not be tolerated in the aromatic ring, activity was retained with a range of *O*-alkyl groups, compounds **6k–t**. In addition, good activity was found for ortho ester **6u** and sulfonamide **6x**. The ortho-substituted phenylureas can therefore be regarded as bioisosteres of the 6,5-heterocycles indole, indazole, and indoline.

In part 1 of this series of papers indazole **1** (BRL 43694) was shown to be a potent and selective 5-hydroxytrypt-




amine 5-HT₃ receptor antagonist.¹ It was also shown to be a highly effective inhibitor of cytotoxic drug and X-irradiation induced emesis in ferrets and is currently being developed as an antiemetic for use in conjunction with anticancer therapy in man. In part 2 we showed that high potency was retained with indolines of general formula **2**.¹ It was concluded that, provided an "in plane" orientation of the carbonyl linkage was not disfavored, aromaticity in the fused 5-membered ring was not necessary. It was therefore considered possible that the 5-membered ring could be replaced by a "pseudo" ring in the form of a hydrogen-bonded system. Although a 5-membered cyclic hydrogen bonded system is weak,² the stabilization af-

Scheme I. Synthesis of Ureas **6a–c**



Scheme II. Synthesis of Ureas **6d–g, i–s, u–z**



fording under suitable conditions may be sufficient to favor an "in plane" orientation of a strategically placed carbonyl linkage.

The present paper describes the synthesis and 5-HT₃ receptor antagonist activity of a series of ortho-substituted phenylureas, **6a–z**, which are capable of forming an intramolecular hydrogen bond.

(1) *J. Med. Chem.* Preceding papers in this issue.

(2) Blaney, F. E.; Clark, M. S. G.; Gardner, D. V.; Hadley, M. S.; Middleton, D.; White, T. J. *J. Med. Chem.* 1983, 26, 1747.